Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30625888 | 0.85 | AR (0.38) | MRGPRX2OPRM1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL11326119 | 0.81 | AR (0.39) | ARBRD4CREBBP | |
| Oxirane SCHEMBL21552079 | 0.78 | GAA (0.39) | MRGPRX2OPRM1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL6539867 | 0.78 | AR (0.38) | SIGMAR1ARBRD4 | |
| Bromide SCHEMBL6028566 | 0.76 | PGR (0.41) | AR | |
| SCHEMBL11371183 | 0.75 | ALDH1A1 (0.44) | AR | |
| SCHEMBL7092850 | 0.75 | SNCA (0.43) | — | |
| SCHEMBL304686 | 0.75 | CA1 (0.38) | AR | |
| SCHEMBL304685 | 0.75 | CA1 (0.38) | AR | |
| SCHEMBL11513542 | 0.74 | MEN1 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387631-A1 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387631-A1 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOF | CD68, MSR1, CD47 | MRGPRX2 171/4885OPRM1 3982/4885OPRD1 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.